Media stories about Cerecor (NASDAQ:CERC) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cerecor earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.3783141044037 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Cerecor (NASDAQ:CERC) traded up $0.38 during midday trading on Wednesday, hitting $2.55. The stock had a trading volume of 2,367,600 shares, compared to its average volume of 563,421. The firm has a market capitalization of $56.54, a price-to-earnings ratio of 217.00 and a beta of 2.99. Cerecor has a 52 week low of $0.34 and a 52 week high of $2.83.
CERC has been the topic of a number of research analyst reports. ValuEngine raised Cerecor from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 7th. TheStreet raised Cerecor from an “e+” rating to a “c-” rating in a research report on Wednesday, November 8th.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Cerecor (CERC) Stock Price” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.com-unik.info/2017/12/20/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-cerecor-cerc-stock-price.html.
Cerecor Company Profile
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.